Scarica l'app Stockscreener
3.89
4.57%
0.17
Precedente Chiudi:
$3.72
Aprire:
$3.65
Volume 24 ore:
452.95K
Relative Volume:
0.59
Capitalizzazione di mercato:
$104.91M
Reddito:
-
Utile/perdita netta:
$-49.81M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-42.93M
1 W Prestazione:
+1.57%
1M Prestazione:
-8.90%
6M Prestazione:
-64.80%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.65
$3.93
Intervallo di 1 settimana:
$3.56
$4.09
Portata 52W:
$3.56
$24.00
Alto Neuroscience Inc Stock (ANRO) Company Profile
Nome
Alto Neuroscience Inc
Settore
Industria
Telefono
773-255-5012
Indirizzo
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Confronta ANRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
3.89 | 104.91M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-23 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-09-03 | Iniziato | Wedbush | Outperform |
| 2024-02-27 | Iniziato | Jefferies | Buy |
| 2024-02-27 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-27 | Iniziato | Stifel | Buy |
| 2024-02-27 | Iniziato | TD Cowen | Outperform |
| 2024-02-27 | Iniziato | William Blair | Outperform |
Mostra tutto
Alto Neuroscience Inc Borsa (ANRO) Ultime notizie
Franklin Resources Inc. Purchases 595,673 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Position Boosted by BNP Paribas Financial Markets - Defense World
Jones Trading sets Alto Neuroscience shares at Buy on portfolio By Investing.com - Investing.com Canada
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Alto Neuroscience, Inc. (NYSE:ANRO) Sees Significant Drop in Short Interest - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $20.00 Average PT from Analysts - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology - BioSpace
Alto Neuroscience Unveils Breakthrough Precision Psychiatry Data at Major Neuroscience Conference - StockTitan
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm - The Eastern Progress Online
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm - The Eastern Progress Online
Fmr LLC Boosts Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Jennison Associates LLC Buys 370,612 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - MarketBeat
Alto Neuroscience (NYSE:ANRO) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
What is William Blair's Forecast for ANRO FY2024 Earnings? - MarketBeat
Wedbush Equities Analysts Reduce Earnings Estimates for ANRO - MarketBeat
RA Capital Management Reduces Stake in Alto Neuroscience Inc - GuruFocus.com
Stifel Nicolaus Has Lowered Expectations for Alto Neuroscience (NYSE:ANRO) Stock Price - MarketBeat
FMR LLC Acquires Shares in Alto Neuroscience Inc - GuruFocus.com
Alto Neuroscience Reports $182M Cash Position Despite Widening Losses in Q3 | ANRO Stock News - StockTitan
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Yahoo Finance
Latest Company News - Investing.com
Largest borrow rate increases among liquid names - TipRanks
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Alto Neuroscience to Participate in Upcoming Investor Conferences - StockTitan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Connect - AccessWire
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Learn More About the Investigation - AccessWire
Alto Neuroscience, Inc. (ANRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Alto Neuroscience, Linkage Global, Pixie Dust: Top 3 Stocks With Explosive Retail Follower Growth Last Week - Barchart
Alto Neuroscience, Inc. (NYSE:ANRO) Short Interest Up 29.9% in October - MarketBeat
Q1 EPS Estimates for Alto Neuroscience Lowered by Wedbush - MarketBeat
Alto Neuroscience stock crashes amid failed study and Wedbush downgrade - MSN
William Blair Has Negative Outlook for ANRO FY2028 Earnings - MarketBeat
Alto Neuroscience’s depression drug trial fails at phase 2 - BioPharma-Reporter.com
Alto Neuroscience sinks as ALTO-100 misses goal in MDD - The Pharma Letter
Wedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readout - Yahoo Finance
RODMAN&RENSHAW Lowers Alto Neuroscience (NYSE:ANRO) to Hold - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News
Alto depression drug failure sends shares plunging 66% - Green Market Report
Gold Moves Lower; AT&T Earnings Top Views - MSN
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
2024-10-23 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Connect | NYSE:ANRO | Press Release - Stockhouse Publishing
Alto Neuroscience stock downgraded by Rodman & Renshaw on trial miss, PT slashed - Investing.com
Alto Neuroscience stock crashes amid failed study and Wedbush downgrade (NYSE:ANRO) - Seeking Alpha
Alto Hits The Wrong Note In Depression - Scrip
Alto Neuroscience Inc Azioni (ANRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):